Skip to main content

Cancer Open Access Research: ASCO 2018

New Content ItemWe will be exhibiting at the ASCO Annual Meeting from June 1-5, Chicago, IL. 

We will be delighted for you to stop by with any questions: come and visit us at stand 20121.

Journal News

New Content Item2018 marks the 10 year anniversary since the Journal of Hematology & Oncology published its first article. Over the past decade, the journal has established itself in the top quartile of journals in both its fields worldwide. 

To mark this occasion, we're looking back at the journal's milestone achievements and highlighting some of the best content from the past 10 years.

View the infographic here.

Our Latest Collections

New Content ItemEmerging biomarkers in oncology research and practiceCancer Cell International is accepting submissions for a thematic series on 'Emerging biomarkers in oncology research and practice'. Guest edited by Dr Aejaz Nasir, the series aims to cover cutting-edge developments in the field of oncology and pathology with reference to diagnostic, prognostic, predictive and pharmacodynamics biomarkers.

New Content ItemCurrent Treatment Algorithms: Current Treatment Algorithms is a new series published in Blood Cancer Journal which is dedicated to providing clear, authoritative and concise treatment pathways for hematologic malignancies.

New Content ItemOncogenic Signaling of Tyrosine Kinase in Cancer: Challenges and Therapeutic Opportunities: Molecular Cancer is excited to present a series of original research and review articles that serves as an intellectual road map in the field of molecular oncology. The role of receptor tyrosine kinases (RTKs) in cancer began only about three decades ago; however, the amount of research and progress dedicated to the study of RTKs has been explosive, considering the vast quantity of known RTKs and their unique mechanisms in manipulating cellular signaling pathways. These articles report on all aspects related to expression, regulation and function of receptor tyrosine kinases (RTKs), non-receptor tyrosine kinases and other kinases in oncogenic signaling in cancer cells. The series aims to highlight significant and quality new findings related to targeted therapies, tyrosine kinase inhibitors (TKI), genetic and epigenetic mechanisms of acquired resistance to TKI, clinical trials and pre-clinical studies.

Featured Articles

Oncology Open Access Research

BMC: cancer researchOur Oncology page showcases the latest journal news, collections, highlights and recent campaigns in our open access cancer research journals.

Oncology Research